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In 2009, the Department of Health asked the MRC and
MHRA to identify major obstacles to non-commercial
clinical trials research in the UK and suggest remedial
actions. Risk-proportionality in trial management and
monitoring was identified as a key area and a sub-group
formed to:
￿ Develop a process to facilitate the agreement of key
stakeholders on the level of risk associated with a clini-
cal trial of an investigational medicinal product
(CTIMP).
￿ Identify how risk-adapted approaches for CTIMPs
can be achieved within the current regulatory
framework.
￿ Develop guidance on risk assessment and the risk-
proportionate management of clinical trials.
The resulting guidance focuses on the risks inherent
in a trial protocol which impact on participant safety
and rights, and the reliability of the results. A two-part
assessment is suggested: 1) a simple IMP risk categorisa-
tion based on marketing status and standard medical
care, and 2) assessment of the trial design, population
and procedures to identify specific areas of vulnerability.
The first part, IMP risk category, has implications for
simplifications of initiation and conduct of a CTIMP
that may be possible within the current regulatory fra-
mework. Possible risk-adaptations include: the need for
competent authority authorisation; content of the Clini-
cal Trials Authorisation (CTA) application; IMP
management; safety surveillance; trial documentation;
and GCP Inspection. The risks associated with the IMP
also determine trial procedures for monitoring partici-
pant safety.
The second part of the risk assessment addresses
other aspects of clinical trial design and methods: safety
risks from clinical procedures; risks related to partici-
pant rights; and risks to the reliability of trial results. It
is designed to help trialists identify potential vulnerabil-
ities and to prepare tailored trial management and mon-
itoring plans to minimise risks which may be reviewed
and modified throughout the life of a trial.
The IMP risk category and safety monitoring plan
may be submitted to the MHRA with the CTA applica-
tion to ensure that there is shared understanding on
this key aspect of a trial. We hope that the entire risk
assessment and associated plans will provide the basis
for a common understanding of stakeholders of the
risks for that trial, and facilitate a risk-proportionate
approach to trial activities.
The guidance is available on the MHRA and NETSCC
websites.
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